Search
Menu
Home
HTB
2009
February
09
HTB
9 February 2009
Contents
Antiretrovirals
Maraviroc safety label changes included with US traditional approval
US approval of paediatric abacavir
EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease
Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA
PK and drug interactions
Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir
Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir
Drug interactions with integrase inhibitors
Drug interactions between efavirenz and itraconazole
Effect on tacrolimus when switching from nelfinavir to fosamprenavir